Seizure frequency in pregnant women treated with lamotrigine monotherapy
Authors:
Open Access
- 21 August 2009
- Vol. 50 (9) , 2163-2166
Abstract
Summary: Previous studies have demonstrated that the pharmacokinetics of the new antiepileptic drug (AED) lamotrigine (LTG) are substantially influenced by pregnancy and are more likely to be associated with seizure deterioration in pregnancy compared to other AEDs. This is of great concern, as LTG has developed into a first‐line AED for women of childbearing age. In this study we evaluated the risk of seizure deterioration in a cohort of women treated with LTG monotherapy (n = 42) who were closely monitored with frequent dose adjustments based on monthly routine plasma level determinations. It was demonstrated that with this close monitoring set‐up, the risk of increased seizure frequency (19%) was not higher than that reported for other AED treatment regimens.Keywords
This publication has 9 references indexed in Scilit:
- Pregnancy and epilepsy: a retrospective study of 151 pregranciesActa Neurologica Scandinavica, 2009
- Lamotrigine in pregnancyNeurology, 2008
- Effects of pregnancy and contraception on lamotrigine disposition: New insights through analysis of lamotrigine metabolitesSeizure: European Journal of Epilepsy, 2008
- Foetal malformations and seizure control: 52 months data of the Australian Pregnancy RegistryEuropean Journal of Neurology, 2006
- Seizure control and treatment in pregnancyNeurology, 2006
- Individual changes in lamotrigine plasma concentrations during pregnancyEpilepsy Research, 2005
- Lamotrigine in Pregnancy: Pharmacokinetics During Delivery, in the Neonate, and During LactationEpilepsia, 2000
- Congenital malformations due to antiepileptic drugsEpilepsy Research, 1999
- Epilepsy and Pregnancy: A Prospective Study of Seizure Control in Relation to Free and Total Plasma Concentrations of Carbamazepine and PhenytoinEpilepsia, 1994